Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers)
Description
Kalorama Information’s Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 provides a comprehensive analysis of the worldwide clinical diagnostic biomarker market, with forecasts from 2022 through 2031. The report examines diagnostic substances and tests used for disease detection, therapy selection, disease monitoring, and evaluation of treatment effectiveness across seven major product categories: infectious diseases, cancer, cardiovascular diseases, general clinical chemistry analytes, neurological conditions, autoimmune conditions, and other conditions such as diabetes, metabolic disorders, fertility, pregnancy, kidney disorders, inherited diseases, and thyroid conditions.
Global and regional sales data—along with projections for the U.S., Europe, China, India, and Japan—are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.
The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.
With in-depth segmentation, market trends, and strategic insights, Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers) serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.
Global and regional sales data—along with projections for the U.S., Europe, China, India, and Japan—are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.
The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.
With in-depth segmentation, market trends, and strategic insights, Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers) serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.
Table of Contents
260 Pages
- About Kalorama Information
- Report Coverage
- Global Biomarker Sales, by Product Group & Region, 2022-2031 ($ million) [Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other] &[Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America]
- Overview
- Biomarker Technologies
- Biomarker Market Analysis
- Overview
- Infectious Disease Biomarker Technologies
- Key Biomarkers for Infectious Disease
- Market Analysis
- Biomarker Product Suppliers
- Overview
- Key Biomarkers for Cancer
- Recent Developments
- Market Analysis
- Biomarker Product Suppliers
- Overview
- Key Biomarkers for Cardiovascular Conditions
- Recent Developments
- Market Analysis
- Overview
- Key Biomarkers for Clinical Chemistry
- Recent Developments
- Market Analysis
- Biomarker Product Suppliers
- Overview
- Key Biomarkers for Neurological Conditions
- Recent Developments
- Market Analysis
- Overview
- Key Biomarkers for Autoimmune Diseases
- Recent Developments
- Market Analysis
- Overview
- Key Biomarkers for Other Conditions
- Market Analysis
- IVD Biomarker-Related Sales of Selected Industry Leaders, 2024 ($ million)
- Abbott Diagnostics
- Asuragen (Bio-Techne)
- Becton Dickinson, and Company
- Bio-Rad Laboratories
- Biocartis
- Biodesix
- bioMérieux
- Biotheranostics, Inc. (Hologic)
- Danaher Corporation
- DiaSorin Group
- Exact Sciences
- Exosome Diagnostics (Bio-Techne)
- Illumina
- Myriad Genetics
- QuidelOrtho
- Qiagen
- Roche Diagnostics
- Siemens Healthineers
- Sysmex Inostics
- Thermo Fisher Scientific
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
